GSK/$GSK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GSK
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
$GSK
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
68,629
ISIN
US37733W2044
Website
GSK Metrics
BasicAdvanced
$73B
35.57
$1.02
0.27
$1.58
4.71%
Price and volume
Market cap
$73B
Beta
0.27
52-week high
$44.67
52-week low
$31.72
Average daily volume
5.5M
Dividend rate
$1.58
Financial strength
Current ratio
0.868
Quick ratio
0.575
Long term debt to equity
120.653
Total debt to equity
134.993
Dividend payout ratio (TTM)
78.91%
Interest coverage (TTM)
10.32%
Profitability
EBITDA (TTM)
11,604.149
Gross margin (TTM)
71.92%
Net profit margin (TTM)
10.00%
Operating margin (TTM)
19.83%
Effective tax rate (TTM)
13.90%
Revenue per employee (TTM)
$616,810
Management effectiveness
Return on assets (TTM)
6.55%
Return on equity (TTM)
27.10%
Valuation
Price to earnings (TTM)
35.574
Price to revenue (TTM)
3.506
Price to book
3.89
Price to tangible book (TTM)
-6.1
Price to free cash flow (TTM)
27.264
Free cash flow yield (TTM)
3.67%
Free cash flow per share (TTM)
133.18%
Dividend yield (TTM)
4.36%
Forward dividend yield
4.71%
Growth
Revenue change (TTM)
2.57%
Earnings per share change (TTM)
-30.07%
3-year revenue growth (CAGR)
5.66%
10-year revenue growth (CAGR)
3.20%
3-year earnings per share growth (CAGR)
-15.47%
10-year earnings per share growth (CAGR)
-11.61%
3-year dividend per share growth (CAGR)
-12.88%
10-year dividend per share growth (CAGR)
-4.67%
What the Analysts think about GSK
Analyst ratings (Buy, Hold, Sell) for GSK stock.
Bulls say / Bears say
GSK's strategic investment in artificial intelligence and supply chain enhancements aims to boost productivity and mitigate potential U.S. tariffs, positioning the company for sustained growth. (ft.com)
The European Medicines Agency's acceptance of GSK's application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older could significantly increase the vaccine's market reach and revenue potential. (reuters.com)
GSK's commitment to reducing the price of its malaria vaccine, Mosquirix, to below $5 per dose by 2028 demonstrates a strategic move to capture a larger share of the global vaccine market, particularly in sub-Saharan Africa. (reuters.com)
The discontinuation of the experimental lung cancer therapy, belrestotug, due to insufficient efficacy in clinical trials, represents a setback in GSK's oncology pipeline and could impact future revenue streams. (reuters.com)
A U.S. Senator's investigation into GSK's decision to remove the children's asthma inhaler, Flovent HFA, from the market raises concerns about potential legal and reputational risks, which could affect the company's financial performance. (reuters.com)
GSK's stock experienced a significant drop of 5.3% in pre-market trading on April 9, 2025, indicating a notable decline in investor sentiment and potential challenges in maintaining shareholder confidence. (ainvest.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
GSK Financial Performance
Revenues and expenses
GSK Earnings Performance
Company profitability
GSK News
AllArticlesVideos
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
WSJ·3 days ago
GSK shares analysts get out the red pens after FDA knock-back wipes £3bn from drug maker's value
Proactive Investors·3 days ago
GSK shares slide 6% after US panel rejects key cancer drug combination
Proactive Investors·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GSK stock?
GSK (GSK) has a market cap of $73B as of July 21, 2025.
What is the P/E ratio for GSK stock?
The price to earnings (P/E) ratio for GSK (GSK) stock is 35.57 as of July 21, 2025.
Does GSK stock pay dividends?
Yes, the GSK (GSK) stock pays dividends to shareholders. As of July 21, 2025, the dividend rate is $1.58204 and the yield is 4.71%. GSK has a payout ratio of 78.91% on a trailing twelve-month basis.
When is the next GSK dividend payment date?
The next GSK (GSK) dividend payment date is unconfirmed.
What is the beta indicator for GSK?
GSK (GSK) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.